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Irregular Lipomatous Extremity Tumor
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A 71-year-old otherwise healthy female presents with an enlarging, 
painless mass in her right gluteal area. On exam, she has a large, 
immobile, non-tender right gluteal mass. She has no neurovascular 
deficits. CT reveals an 11cm heterogeneous lipomatous tumor 
involving the right gluteal musculature. What is the differential 
diagnosis and what would you do next?
Case Scenario
A 71-year-old otherwise healthy female presented with an enlarging, 
immobile, painless mass in her right gluteal area. She has no other 
associated symptoms. On exam, she has a large, palpable, non-tender 
right gluteal mass. She has no neurovascular deficits. Laboratory 
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studies are within normal limits. CT reveals an 11cm heterogeneous 
lipomatous tumor involving the right gluteal musculature (Figure 1).
What Would You Do Next?
A. Incisional biopsy of the lesion
B. Core-needle biopsy of the lesion
C. Simple excision of the lesion
D. Repeat imaging in 6 months
Diagnosis: Well-differentiated / de-differentiated liposarcoma 
What to Do Next: 
B. Core-needle biopsy of the lesion
Core-needle biopsy should be performed to obtain tissue diagnosis. 
Incisional biopsy should be avoided and can complicate surgical and 
oncologic management (1). Surgical management should be deferred 
until a tissue diagnosis is made and pre-operative workup is complete. 
As this tumor is enlarging, >5cm, deep (sub-fascial), and 
heterogeneous, it should be considered malignant until proven 
otherwise. Repeat imaging is unnecessary and inadequate.
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Discussion
Liposarcomas are rare, often aggressive, malignancies that 
require surgical resection and multidisciplinary management. There 
are approximately 2,400 new cases of liposarcoma diagnosed in the 
United States per year (2, 3). Subtypes of liposarcoma include well-
differentiated, de-differentiated, myxoid, and pleomorphic. Of note, a 
well-differentiated liposarcoma of the extremity may also be referred 
to as an atypical lipomatous tumor.
As with all soft tissue sarcomas, liposarcomas are most 
frequently found on the extremities or in the retroperitoneum. 
Lipomatous tumors are relatively asymptomatic. A lipomatous tumor 
arising in the extremity typically presents as a painless mass and in 
the retroperitoneum occasionally with vague abdominal symptoms.
Cross-sectional imaging, either CT or MRI, should be obtained for 
all patients. Extremity tumors that are large (>5cm), sub-fascial, or 
enlarging and any retroperitoneal mass should be considered 
malignant until proven otherwise. In most cases, core-needle biopsy 
should be obtained for tissue diagnosis. Incisional biopsy should be 
avoided and can complicate surgical and oncologic management (1). 
MDM2 amplification, detected by fluorescence in situ hybridization 
(FISH), can provide additional information. This is particularly useful in 
distinguishing a well-differentiated liposarcoma (MDM2 amplification) 
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from a benign lipoma (no MDM2 amplification), as this is often a 
difficult histologic and/or radiologic distinction (4). De-differentiated 
(MDM2 amplification), myxoid (no MDM2 amplification), and 
pleomorphic (no MDM2 amplification) liposarcomas have more 
characteristic appearances on histology and imaging, so MDM2 
amplification may be less useful in these cases. 
All patients diagnosed with liposarcoma should undergo CT of the
chest to complete pre-operative staging, as sarcomas spread 
hematogenously, most frequently to the lung. A chest x-ray may be an 
appropriate substitute for CT of the chest for patients diagnosed with 
an extremity well-differentiated liposarcoma / atypical lipomatous 
tumor. Patients diagnosed with myxoid liposarcoma should additionally
undergo CT of the abdomen/pelvis and be considered for MRI spine, as 
this liposarcoma subtype can metastasize to other anatomic locations. 
Surgery remains the mainstay of treatment for liposarcoma and 
oncologic margin-negative resection is associated with improved 
disease-free survival. Amputation is rarely, if ever, required for primary
extremity disease. Identifying malignant tumors pre-operatively is 
critical for surgical planning and avoiding unnecessarily morbid 
operations to obtain local control. A patient that undergoes a simple 
excision for a presumed lipoma that is found to be a liposarcoma 
should undergo repeat imaging and often a wide re-resection of the 
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surgical site as there is a 50-80% rate of gross residual disease in this 
setting (5).
Radiation therapy has been shown to improve local control for 
patients with primary high-grade extremity soft tissue sarcomas, 
including liposarcomas. However, the exceptions of the use of radiation
are small, low-grade liposarcomas or well-differentiated liposarcomas / 
atypical lipomatous tumors, given their low risk of recurrence and the 
potential long-term complications from radiation (6). Although the 
benefit is less clear for retroperitoneal disease, radiation may be used 
in highly selected cases for the treatment of aggressive histologic 
subtypes by centers with expertise in treating sarcoma in this location.
For both the extremity and retroperitoneum, pre-operative 
(neoadjuvant) radiation is preferred due to its favorable late toxicity 
profile, shorter course, and potential operative benefits of downsizing 
the tumor (7). The benefit of systemic therapy (chemotherapy, 
molecularly-targeted therapy, or immunotherapy) for high-risk 
liposarcomas is less clear and is only considered for specific histologic 
subtypes or for patients with metastatic or locally advanced disease 
(8). 
Risk of local recurrence (5% to 15%) and distant metastasis (5% 
to 70%) of extremity liposarcomas ranges widely and is dependent on 
the histologic subtype, grade and size. In comparison to extremity 
liposarcomas, the risk of local recurrence for retroperitoneal 
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liposarcomas is significantly higher (40% to 50%). Widely-validated 
prognostic models or nomograms more accurately determine oncologic
prognosis than existing TNM staging systems. Websites, such as the 
MSKCC nomogram, and applications, such as Sarculator (which uses 
validated nomogram data), give patient-specific prognosis data and 
are utilized by sarcoma oncologists and patients alike (9). 
A patient that is diagnosed with liposarcoma should be referred 
to a sarcoma specialty center whenever possible, as multidisciplinary 
treatment and surveillance by physicians specializing in sarcoma has 
been shown to improve patient outcomes (10).
Patient Outcome
Core-needle biopsy revealed a spindle and pleomorphic sarcoma,
most consistent with a well-differentiated / de-differentiated 
liposarcoma with MDM2 amplification present. CT of the chest showed 
no systemic disease. After a multidisciplinary discussion, the patient 
underwent neoadjuvant radiation followed by resection. She has 
undergone surveillance imaging every 6 months since her surgery and 
remains disease free two years post-operatively.
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Figures
  
Figure 1: Axial and coronal CT of a large, heterogeneously enhancing 
right gluteal mass. 
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